Table 1.
CAR T-cell Clinical Trials for Pancreatic Cancer
| Target | Institution | Preconditioning | Costim domain | Human/Mouse scFv | Population | Estimated completion | Route | Outcomes | Reference |
|---|---|---|---|---|---|---|---|---|---|
| Mesothelin | NCI | Cy/Flu | CD28 | Murine | PDAC, ovarian, and mesothelioma | 2019 | IV | N/A | NCT01583686 |
| Mesothelin | MSKCC | Cy | CD28 | Human | PDAC, breast, mesothelioma | 2018 | IV | N/A | NCT02792114 Pending |
| Mesothelin | UPenn | None | 4-1BB | Murine | Chemo-refractory metastatic PDAC | 2015 | IV | 1 PDAC patients reported; no off target toxicity; transient PET response and temporary reduction in ascites tumor burden. | NCT01897415 |
| Mesothelin | UPenn | With/without Cy | 4-1BB | Murine | PDAC failed at least one treatment | 2017 | IV | N/A | NCT02159716 |
| Mesothelin, CD19 | UPenn, UCSF | Cy | 4-1BB | Murine Mesothelin with Humanized CD19 | PDAC | 2018 | IV | N/A | NCT02465983 |
| Mesothelin | Renji Hospital, China | Cy | 4-1BB | N/A | PDAC, non-surgical candidate failed at least one treatment | 2018 | Trans-cathether arterially infused | N/A | NCT02706782 |
| Mesothelin | Shanghai Cancer Hospital, China | N/A | N/A | N/A | PDAC spread to liver, non-surgical candidate, failed at least one chemo | 2018 | Intratumoral injection or vascular IR delivery | N/A | NCT01897415 |
| Mesothelin | Chinese PLA General Hospita, China | N/A | N/A | N/A | Relapsed or refractory mesothelin positive cancer | 2018 | IV | MTD | NCT02580747 |
| PSCA | Baylor Sammons Cancer Center | N/A | AP1903 inducible MyD88/CD40 | N/A | Non-resectable PDAC | 2020 | IV | N/A | NCT02744287 |
| CEA | Roger Williams Medical Center, RI | N/A | CD28 | N/A | CEA expressing carcinomas with liver mets | 2017 | Hepatic artery | N/A | NCT02850536, NCT02416466 |
| CEA | Southwest Hospital, China | N/A | N/A | N/A | Relapsed or refractory CEA positive PDAC | 2019 | IV | N/A | NCT02349724 |
| Muc1 | Hefei Binhu Hospital, China | Cy/Flu | CD28/4-1BB | Murine | PDAC without curative options; non-R1 resected PDAC | 2018 | N/A | N/A | NCT02587689 |
| CD133 | Chinese PLA General Hospita, China | Nab-Paclitaxel and Cy | 4-1BB | Murine | Refractory or relapsed CD133 positive cancer | 2018 | N/A | MTD | NCT02541370 |
| HER2 | Southwest Hospital, China | N/A | N/A | N/A | Relapsed or refractory HER2 positive cancer | 2019 | IV | MTD | NCT02713984 |
Definitions: CEA, carcinoembryonic antigen; PSCA, prostate stem cell antigen; Muc1, mucin 1; HER2, human epidermal growth factor receptor 2; MTD, maximum tolerated dose; Cy, cyclophosphamide; Flu, fludarabine